Nasdaq:US$38.93 (+1.39) | HKEX:HK$60.10 (+0.40) | AIM:£5.56 (+0.14)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors